|
|
|
|
Genzyme plays down latest Cerezyme impurity
Genzyme has just revealed that it found an impurity in a single vial of its Gaucher's disease drug Cerezyme (imiglucerase) from its fill-finish facility in Wate Genzyme plays down latest Cerezyme impurity.
|
|
|
Genzyme addresses impurity problem at Ireland Cerezyme plant
Related topics: Processing & QC US drugmaker Genzyme has detected an impurity in one vial of the Gauchers disease drug Cerezyme produced at its manufacturing facility in Waterford, Ireland.According to media reports Genzyme found a chemical...
|
|
|
Genzyme inspection finds drug impurity
Genzyme Corp.has notified its customers that an impurity has been found in one vial of the drug Cerezyme at its plant in Waterford, Ireland, in what is the latest in a series of manufacturing problems for the biotechnology company. The notification, posted...
|
|
|
BRIEF: Eli Hurvitz steps down from Protalix: Hurvitz's departure severs Protalix's last tie with Teva.
Symbols: TEVA, PFE Do you know when to trade TEVA & PFE?Mar 10, 2010 (Globes - McClatchy-Tribune Information Services via COMTEX) -- Eli Hurvitz today announced his resignation as chairman of Protalix Biotherapeutics Inc? (AMEX:PLX), following his...
|
|
|
Shire Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report
www.companiesandmarkets.com/Summary-Company-Profile/shire-plc-ph ..Shire Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the companys key business structure...
|
|
|
Protalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors
CARMIEL, Israel 'We are very thankful to have had Mr.Eli Hurvitz Mr. Bronfeld became the Company's first investor and director in 1996. , As a seasoned healthcare investor, Mr. Bronfeld brings vast experience in management and value building of...
|
|
|
Pharma Reassesses Orphan Drug Sector
Drug Firms Are Aggressively Seeking Replacements for Dwindling Blockbusters Benjamin J.Conway click to enlarge Through 2002, the number of drugs seeking orphan drug designation remained relatively consistent. As evidenced by the recent licensing deal...
|
|
|
Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
CARMIEL, Israel, March 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc.(NYSE-Amex: PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Companyescape_start39;s...
|
|
|
Replacement Therapy Approved for Gaucher Disease
_ Replacement Therapy Approved for Gaucher Disease.
|
|
|
FDA Approves Therapy to Treat Gaucher Disease
_ FDA Approves Therapy to Treat Gaucher Disease.
|
|
|
Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
CARMIEL, Israel, March 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc.(NYSE-Amex: PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Company's manufacturing facility...
|
|
|
Protalix Completes Audit Of Manufacturing Facility In Israel
Protalix BioTherapeutics said that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of its manufacturing facility in Carmiel, Israel.The audit was performed as part of the Ministry of Health's evaluation of...
|
|
|
FDA Approves Therapy to Treat Gaucher Disease
New drug will offer a treatment alternative for patients with rare genetic disorder SILVER SPRING, Md., Feb.26 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and...
|
|
|
Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
CARMIEL, Israel, March 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc.(NYSE-Amex: PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Companyescape_start39;s...
|
|
|
Protalix Announces Successful GMP Manufacturing Audit By Israel's Ministry Of Health
Carmiel, Israel, /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc.(NYSE-Amex: PLX ), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Company's manufacturing facility in...
|
|
|
Shire Announces FDA Approval of VPRIV for Gaucher Disease
- Company Announces New Enhancements to Patient Assistance Programs in the United States LONDON, March 1, 2010-Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the U.S.Food and Drug Administration (FDA...
|
|
|
FDA Approves Therapy to Treat Gaucher Disease
_ FDA Approves Therapy to Treat Gaucher Disease.
|
|
|
Injectable velaglucerase alfa approved to treat Gaucher disease
_ Injectable velaglucerase alfa approved to treat Gaucher disease.
|
|
|
Protalix Announces Successful GMP Manufacturing Audit by Israel's Ministry of Health
CARMIEL, Israel, March 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc.(NYSE-Amex: PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice) audit of the Company's manufacturing facility...
|
|
|
Shire Supports Rare Disease Day 2010
/PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and...
|
|
|
FDA Approves Therapy to Treat Gaucher Disease
_ FDA Approves Therapy to Treat Gaucher Disease.
|
|
|
The Incompetent Monopolist: Genzyme's Drug Screwups Invite Attacks by Shire, Pfizer
The FDA approved Shire (SHPGY)'s Gaucher disease drug, Vpriv, on Feb.27, allowing the U.K. The Incompetent Monopolist: Genzyme's Drug Screwups Invite Attacks by Shire, Pfizer.
|
|
|
Shire Announces FDA Approval of VPRIV for Gaucher Disease
- Company Announces New Enhancements to Patient Assistance Programs in the United States LONDON, March 1, 2010-Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the U.S.Food and Drug Administration (FDA...
|
|
|
New Type 1 Gaucher Disease Treatment Approved
The FDA has approved Shire Human Genetic Therapies VPRIV (velaglucerase alfa for injection), a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy in pediatric and adult patients with type 1 Gaucher...
|
|
|
Shire Supports Rare Disease Day 2010
/PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and...
|
